AgingResearch.NewsJoin free

Candel Therapeutics

CompanyUnited States

Wikidata

Candel Therapeutics develops one asset, in phase 2 (aglatimagene besadenovec in non-small cell lung cancer). Mostly gene therapy acting on apoptosis; based in the United States.

1
Asset
Furthest stage
Phase 2
0
Trials
0
Signals

Pipeline

1

  • aglatimagene besadenovec

    Adenoviral vector expressing HSV-tk combined with valacyclovir to induce tumor cell death and immune reactivation.

    Phase 2, Gene therapy, Apoptosis, non-small cell lung cancer

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Similar companies6

Intelligence